Skip to main content

Table 2 Summary of findings and strength of evidence in studies

From: Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Outcome

No. of patients (Trials)

RR/MD (95% CI)

I2

Absolute effect estimates (per 1000)

Quality of the evidence

Intervention

Control

Difference

Cardiovascular events

3008 (2)

0.75 [0.56, 0.99]

0%

56

74

− 19 [− 1, − 33]

High

Percent change of LDL-C

3957 (9)

− 22.91 [− 27.35, − 18.47]

99%

–

–

–

Moderate#

New-onset or worsening diabetes

3621 (4)

0.65 [0.44, 0.96]

23%

38

58

− 20 [− 2, − 32]

Moderate§

Percent change of CRP

3555 (7)

− 24.70 [− 32.10, − 17.30]

53%

–

–

–

Moderate#

Myocardial infarction

3008 (2)

0.54 [0.25, 1.15]

37%

12

22

− 10 [− 17, 3]

Moderate§,#

Coronary revascularization

3008 (2)

0.74 [0.50, 1.10]

0%

29

39

− 10 [− 20, 4]

Moderate§

Cardiovascular death

3008 (2)

1.65 [0.46, 5.98]

0%

5

3

2 [− 2, 15]

Moderate§

Nonfatal stroke

3008 (2)

1.11 [0.34, 3.61]

0%

4

4

0 [− 3, 10]

Moderate§

Hospitalization for unstable angina

2574 (2)

0.84 [0.41, 1.73]

51%

11

13

− 2[− 8, 9]

Low#,§

Any adverse event

4188 (9)

1.01 [0.97, 1.05]

40%

712

705

7 [− 21, 35]

Low&,#

Serious adverse event

4184 (9)

1.06 [0.89, 1.26]

0%

126

119

7 [− 13, 31]

Moderate&

Muscular-related adverse event

2703 (3)

1.12 [0.80, 1.56]

26%

120

107

13 [− 21, 60]

Moderate§

Decrease in glomerular filtration rate

3276 (3)

3.61 [0.81, 16.04]

0%

4

1

3 [− 1, 14]

Low*

Increase in blood creatinine

3482 (4)

2.15[0.81, 5.69]

0%

6

3

3 [− 1, 16]

Moderate§

Increase in blood uric acid

1176 (3)

3.76 [1.24, 11.39]

0%

30

8

22 [2,81]

Low*

Gout

3421 (4)

2.37 [0.88, 6.36]

12%

12

5

7 [− 1, 43]

Moderate§

Neurocognitive disorders

3076 (3)

0.94 [0.41, 2.17]

0%

8

8

0 [− 5, 9]

Moderate§

ALT or AST > 3 × ULN

3382 (5)

1.97 [0.61, 6.34]

0%

6

3

3 [− 1, 14]

Moderate§

CK > 5 × ULN

3382 (5)

1.31 [0.23, 7.50]

19%

3

2

1 [− 1, 12]

Moderate§

  1. LDL-C Low density lipoprotein cholesterol, CRP C-reactive protein, CK Creatine kinase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit of the normal range, RR Risk ratio, MD Mean difference
  2. &Publication bias
  3. #Inconsistency
  4. §Imprecision
  5. *Very serious imprecision